At a Glance
| Indication | Hypoxic respiratory failure |
| Drug | Nitric Oxide |
| Mechanism of Action | Vasodilator |
| Company | Beyond Air, Inc. |
| Category | Regulatory Milestone |
| Sub Category | Approval Pending |
| Therapeutic Area | Respiratory |
| Preliminary Revenue Q3 2026 | $2.3 million |
| Quarterly Revenue Growth (Sequential) | 30% |
| Quarterly Revenue Growth (Year-over-Year) | 27% |
| Revenue Guidance CY2026 | $8 million |
| Revenue Guidance CY2027 | $16-$18 million |
| Device Name | LungFit PH |
| Second-Generation System Status | Under FDA review |
| Regulatory Body | FDA |
| Company Stock Exchange | NASDAQ |
| Company Stock Symbol | XAIR |
Beyond Air Reports Record Preliminary Q3 Revenue Driven by LungFit PH
Beyond Air, Inc. announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. This figure represents the highest quarterly revenue reported by the company, showing approximately 30% sequential quarterly growth and 27% growth over the same period last year. The strong performance is attributed to the continued adoption of its first-generation LungFit PH system and enhanced commercial execution. The company reaffirmed its revenue guidance of $8 million for calendar year 2026 and $16-$18 million for calendar year 2027, with the latter including anticipated revenue from its second-generation LungFit PH system, which remains under FDA review.
- Beyond Air achieved its highest quarterly revenue to date, reporting preliminary unaudited revenue of $2.3 million for the quarter ended September 30, 2026. This significant financial performance reflects a robust 30% sequential quarterly growth and a 27% increase compared to the same period last year, primarily driven by the successful implementation of the company's enhanced commercial strategy and the sustained adoption of its first-generation LungFit PH system.
- The company has reaffirmed its financial outlook, maintaining revenue guidance of $8 million for calendar year 2026, which excludes any contribution from the second-generation LungFit PH system. For calendar year 2027, Beyond Air projects revenue between $16 million and $18 million, anticipating the inclusion of revenue from its second-generation system, pending its expected FDA approval. This second-generation system aims to add crucial transport capability, positioning Beyond Air as a single-source nitric oxide provider.
- Beyond Air's LungFit PH is a cylinder-free, phasic flow generator and delivery system that generates nitric oxide from ambient air on demand. The first-generation system is FDA-approved for treating term and near-term neonates with hypoxic respiratory failure and has established a strong track record for reliable NO delivery. This innovative technology offers significant advantages in hospital settings, including reduced inventory, improved safety by eliminating NO2 purging steps, and overall operational benefits.
Frequently Asked Questions
How does inhaled nitric oxide improve oxygenation in hypoxic respiratory failure?
Inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator. It diffuses into the pulmonary vasculature, relaxing smooth muscle cells surrounding the blood vessels in well-ventilated lung regions. This targeted vasodilation redirects blood flow away from poorly ventilated areas, improving ventilation-perfusion matching and thereby enhancing arterial oxygenation.
What are the key clinical indications for inhaled nitric oxide in respiratory distress?
Inhaled nitric oxide is primarily indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. It is also used off-label in adult acute respiratory distress syndrome (ARDS) to improve oxygenation, though its impact on mortality in this population is less clear. Its application aims to reduce the need for extracorporeal membrane oxygenation (ECMO) in neonates.
What are the primary safety considerations for administering inhaled nitric oxide therapy?
Key safety considerations include the potential for methemoglobinemia, which requires regular monitoring of methemoglobin levels. Abrupt discontinuation of iNO can lead to rebound pulmonary hypertension and worsening oxygenation, necessitating careful weaning. Nitric dioxide (NO2) formation, a toxic gas, is another concern, requiring precise delivery and scavenging systems.
How does inhaled nitric oxide fit into the current treatment guidelines for severe hypoxic respiratory failure?
Inhaled nitric oxide is a recognized therapeutic option, particularly in neonatal hypoxic respiratory failure with persistent pulmonary hypertension, where it is a cornerstone of care. For adult acute respiratory distress syndrome (ARDS), iNO is considered a rescue therapy to improve oxygenation in severe cases, often when other strategies have failed. Its role is typically adjunctive to lung-protective ventilation and other supportive measures.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
